A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease

Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta®, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron a license to manufacture and commercialize Eureca-V™ Nuclease, the wild-type MAD7™ CRISPR Type-V nuclease.